| Name | Title | Contact Details |
|---|
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.
PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on ‘on-time project delivery. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines. PSIs global reach allows us to run clinical trials across multiple continents, in 50+ countries around the world. PSIs reputation is that of a no-nonsense CRO focused on timely patient enrollment and project delivery. An exceptionally high repeat and referral business rates alongside low staff turnover are indicative of our commitment to be the best CRO in the world as measured by our clients and our employees. http://www.psi-cro.com
StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity.
Puget Sound Kidney Centers is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world`s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world`s biomedical information to enable the most efficient analysis at scale.